AzTrials
AzTrials

Rhematoid ArthritisPhase 4ORAL STRATEGYNCT02187055

An Efficacy And Safety Study Evaluating Tofacitinib With And Without Methotrexate Compared To Adalimumab With Methotrexate

A Phase 4 study testing Tofacitinib with methotrexate, Tofacitinib without methotrexate and Adalimumab with methotrexate in people with Rhematoid Arthritis, run by Pfizer at 215 sites in 25 countries.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

To assess the efficacy of tofacitinib monotherapy or tofacitinib with methotrexate as compared to adalimumab with methotrexate. To compare the efficacy of tofacitinib monotherapy compared to tofacitinib combined with methotrexate. To compare effects on all health outcomes measures in the study. Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Rhematoid Arthritis
What is being tested?
Tofacitinib with methotrexate, Tofacitinib without methotrexate and Adalimumab with methotrexate
Could I receive a placebo?
No, everyone receives an active treatment
How many people
1,152 participants
Where
215 sitesin 25 countries
Study dates
Aug 2014to Dec 2016
Phase
Phase 4
Are there results?
Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Have moderate to severe rheumatoid arthritis
  • On methotrexate but inadequately controlled
  • Subjects must not have active tuberculosis or an inadequately treated tuberculosis infection
  • Subjects must use contraception

Who cannot join

  • Subjects who have been previously treated with adalimumab or Tofacitinib
  • Subjects with any current malignancy or a history of malignancy, with the exception of adequately treated or excised non metastatic basal cell or squamous cell cancer of the skin or cervical carcinoma in situ.
  • Subjects with specific laboratory test abnormalities
  • Subjects with specific types of infections

Trial locations and contacts

215 sites in 25 countries.

215 sites in 25 countries

United States60 sites
  • AARDS Research, Inc.

    Aventura, Florida, 33180

  • Arthritis and Rheumatic Disease Specialties

    Aventura, Florida, 33180

  • Ochsner Clinic Baton Rouge

    Baton Rouge, Louisiana, 70809

  • Accurate Clinical Management, LLC

    Baytown, Texas, 77521

  • Joao M. A. Nascimento

    Bridgeport, Connecticut, 06606

  • Low Country Rheumatology, PA

    Charleston, South Carolina, 29406

  • Coeur D'Alene Arthritis Clinic

    Coeur d'Alene, Idaho, 83814

  • Medvin Clinical Research

    Covina, California, 91722

  • Arthritis Care And Diagnostic Center, P.A.

    Dallas, Texas, 75231

  • Metroplex Clinical Research Center

    Dallas, Texas, 75231

  • Altoona Center For Clinical Research

    Duncansville, Pennsylvania, 16635

  • Riverside Clinical Research

    Edgewater, Florida, 32132

  • Arthritis and Osteoporosis Treatment and Research Center

    Flowood, Mississippi, 39232

  • Centre for Rheumatology, Immunology and Arthritis

    Fort Lauderdale, Florida, 33309

  • Arthritis Treatment Center

    Frederick, Maryland, 21702

  • St. Jude Hospital Yorba Linda DBA St. Joseph Heritage Healthcare

    Fullerton, California, 92835

  • Arthrocare, Arthritis Care & Research, PC

    Gilbert, Arizona, 85234

  • Accurate Clinical Management, LLC

    Houston, Texas, 77004

  • Rheumatology Clinic of Houston, PA

    Houston, Texas, 77065

  • Houston Institute For Clinical Research

    Houston, Texas, 77074

  • HealthCare Partners Medical Group

    Huntington Beach, California, 92646

  • Rheumatology Associates of North Alabama, PC

    Huntsville, Alabama, 35801

  • Institute of Arthritis Research

    Idaho Falls, Idaho, 83404

  • Diagnostic Rheumatology and Research PC

    Indianapolis, Indiana, 46227

  • West Tennessee Research Institute

    Jackson, Tennessee, 38305

  • Jacksonville Center for Clinical Research

    Jacksonville, Florida, 32216

  • Jasper Clinic

    Kalamazoo, Michigan, 49007

  • Keck Medicine of USC - Division of Rheumatology

    Los Angeles, California, 90033

  • University of Southern California (USC) Norris Comprehensive Cancer Center

    Los Angeles, California, 90033

  • Ronald Reagan UCLA Medical Center - Drug Information Center

    Los Angeles, California, 90095

  • UCLA David Geffen School of Medicine, Division of Rheumatology

    Los Angeles, California, 90095

  • Arthritis & Osteoporosis Associates, LLP

    Lubbock, Texas, 79424

  • Southwest Rheumatology Research, LLC.

    Mesquite, Texas, 75150

  • Trinity Health Center - Medical Arts

    Minot, North Dakota, 58701

  • Arthritis and Diabetes Clinic, Inc

    Monroe, Louisiana, 71203

  • Lynn Health Science Institute

    Oklahoma City, Oklahoma, 73112

  • Omega Research Consultants, LLC

    Orlando, Florida, 32804

  • Arthritis Center, Inc.

    Palm Harbor, Florida, 34684

  • Gulf Region Clinical Research Institute Llc

    Pensacola, Florida, 32514

  • Arthritis Group

    Philadelphia, Pennsylvania, 19152-3303

  • Medvin Clinical Research

    Placentia, California, 92870

  • Dr. Prem C. Chatpar M.D.,LLC

    Plainview, New York, 11803

  • PMG Research of Salisbury, LLC

    Salisbury, North Carolina, 28144

  • Rowan Diagnostic Clinic

    Salisbury, North Carolina, 28144

  • Accurate Clinical Research, Inc.

    San Antonio, Texas, 78229

  • Arthritis & Osteoporosis Center of South Texas

    San Antonio, Texas, 78232

  • San Diego Arthritis Medical Clinic

    San Diego, California, 92108

  • Arthritis Northwest, PLLC

    Spokane, Washington, 99204

  • Clinvest/ A Division of Banyan Group, Inc.

    Springfield, Missouri, 65807

  • St. Louis Center For Clinical Research Barbara Caciolo, MD

    St Louis, Missouri, 63128

  • West Broward Rheumatology Associates, Inc.

    Tamarac, Florida, 33321

  • BayCare Medical Group Inc

    Tampa, Florida, 33614

  • Inland Rheumatology Clinical Trials, Inc.

    Upland, California, 91786

  • Medvin Clinical Research

    Van Nuys, California, 91405

  • Deerbrook Medical Associates

    Vernon Hills, Illinois, 60061

  • The Center for Arthritis and Rheumatism

    Vero Beach, Florida, 32960

  • The Office of Alastair C. Kennedy, MD

    Vero Beach, Florida, 32960

  • Medvin Clinical Research

    Whittier, California, 90602

  • PMG Research of Wilmington

    Wilmington, North Carolina, 28401

  • Advanced Clinical Research of Orlando, Inc.

    Winter Garden, Florida, 34787

Other trials in United States

Poland14 sites
  • Szpital Uniwersytecki nr 2 im. dr Jana Biziela w Bydgoszczy,

    Bydgoszcz, 85-168

  • Centrum Medyczne SILESIANA Sp. z o.o.

    Bytom, 41-902

  • Nzoz Bif-Med

    Bytom, 41-902

  • Centrum Kliniczno-Badawcze J.Brzezicki, B.Gornikiewicz-Brzezicka

    Elblag, 82-300

  • Synexus Polska Sp. z o.o. Oddzial w Gdyni

    Gdynia, 81-384

  • Synexus Polska Sp. z o.o. Oddzial w Katowicach

    Katowice, 40-040

  • Medica Pro Familia Sp. z o.o. S.K.A. Oddzial Krakow

    Krakow, Malopolska, 30-002

  • Centrum Terapii Wspolczesnej J.M. Jasnorzewska Spolka Komandytowo-Akcyjna

    Lodz, 90-242

  • Lecznica MAK-MED, NZOZ

    Nadarzyn, 05-830

  • Prywatna Praktyka Lekarska

    Poznan, 61-397

  • Centrum Medyczne Amed

    Warsaw, WOJ Mazowieckie, 01-518

  • Synexus Polska Sp. z o.o. Oddzial w Warszawie

    Warsaw, 01192

  • MTZ Clinical Research Sp. z o.o.

    Warsaw, 02-106

  • Synexus Polska Sp. z o.o. Oddzial we Wroclawiu

    Wroclaw, 50-088

Other trials in Poland

Russia14 sites
  • SAHI of KR "Kemerovo Regional Clinical Hospital"

    Kemerovo, 650066

  • SBEI HPE First Moscow State Medical University n.a.I.M.Sechenov of MoH of RF based on UCH#1

    Moscow, 119991

  • CJSC "European Medical Center"

    Moscow, 129090

  • SBEI HPE Novosibirsk State Medical University of MoH of RF

    Novosibirsk, 630102

  • State Budgetary Healthcare Institution "Orenburg Regional Clinical Hospital"

    Orenburg, 460018

  • Republic Hospital n.a. V.A. Baranov

    Petrozavodsk, Karelia Republic, 185019

  • State Budgetary Healthcare Institution of Karelia Republic "Republic Hospital n.a. V.A. Baranov"

    Petrozavodsk, Karelia Republic, 185019

  • State Budgetary Institution of Ryazan Region "Regional Clinical Cardiology Dispensary"

    Ryazan, 390026

  • Limited Liability Company AVA-PETER

    Saint Petersburg, 191014

  • State Budgetary Institution of Healthcare "Samara Regional Clinical Hospital n.a. V.D. Seredavin"

    Samara, 443095

  • State Institution of Healthcare "Regional Clinical Hospital"

    Saratov, 410053

  • Non-state Healthcare Institution "Regional Hospital at Smolensk Station of OJSC "Russian Railways"

    Smolensk, 214025

  • State Autonomous Healthcare lnstitution of Yarostavl Region

    Yaroslavl, 150003

  • State Budgetary Healthcare Institution of Yaroslavl Region "Clinical Hospital #3"

    Yaroslavl, 150007

Other trials in Russia

Mexico13 sites
  • Investigacion y Biomedica de Chihuahua, SC

    Chihuahua City, 31000

  • Centro de Investigacion de Tratamientos Innovadores de Sinaloa S.C.

    Culiacán, Sinaloa, 80000

  • Centro de Investigacion en Tratamientos Innovadores de Sinaloa S.C.

    Culiacán, Sinaloa, 80000

  • Centro Integral en Reumatologia, SA de CV

    Guadalajara, Jalisco, 44160

  • Centro de Integral en Reumatologia SA de CV

    Jalisco, 44160

  • Centro Multidisciplinario para el Desarrollo Especializado de la Invetigacion Clinica en Yucatan

    Mérida, Yucatán, 97133

  • Departamento de Imagen de Hospital Star Medica Merida

    Mérida, Yucatán, 97133

  • Laboratorio clínico del Hospital Star Medica Merida

    Mérida, Yucatán, 97133

  • Storage for lab kits and study materials

    Mérida, Yucatán, 97133

  • CINTRE, Centro de Investigacion y Tratamiento Reumatologico S.C. Consultorio Medico de Reumatologia

    Mexico City, Mexico City, 11850

  • Centro de Alta Especialidad en Reumatologia e Investigacion del Potosi, S.C.

    San Luis Potosí City, 78213

  • Unidad de Investigaciones Reumatologicas A.C.

    San Luis Potosí City, 78290

  • Unidad de Enfermedades Reumaticas y Cronico Degenerativas S. C.

    Torreón, Coahuila, 27000

Other trials in Mexico

South Africa12 sites
  • Iatros International

    Bloemfontein, Free State, 9301

  • Arthritis Clinical Research Trials

    Cape Town, Western Cape, 7405

  • Panorama Medical Centre

    Cape Town, Western Cape, 7500

  • Netcare St Augustine's Hospital

    Durban, KwaZulu-Natal, 4001

  • LCS Clinical Research Unit

    Johannesburg, Gauteng, 2021

  • WCR: Wits Clinical Research Charlotte Maxeke Johannesburg Academic Hospital

    Johannesburg, Gauteng, 2193

  • WCR: Wits Clinical Research

    Johannesburg, Gauteng, 2193

  • Charlotte Maxeke Johannesburg Academic Hospital

    Parktown, Johannesburg, Gauteng, 2193

  • Clinical Research Unit, University of Pretoria

    Pretoria, Gauteng, 0002

  • Netcare Jakaranda Hospital

    Pretoria, Gauteng, 0002

  • University of Pretoria

    Pretoria, Gauteng, 0002

  • Wineland Medical Research Centre

    Stellenbosch, Western Cape, 7600

Other trials in South Africa

Romania11 sites
  • Spitalul Judetean de Urgenta "Dr. Constantin Opris"

    Baia Mare, Maramureş, 430031

  • S.C. Clinica Somesan S.R.L.

    Baia Mare, Maramureş, 430352

  • Ianuli Med Consult SRL, Reumatologie

    Bucharest, 010976

  • Spitalul Clinic Sf. Maria, Medicina interna - Reumatologie

    Bucharest, 011172

  • Spitalul Clinic Sf. Maria

    Bucharest, 011172

  • Spitalul Clinic "Dr. I. Cantacuzino"

    Bucharest, 020475

  • Centrul Clinic de Boli Reumatismale "Dr. Ion Stoia"

    Bucharest, 020983

  • Spitalul Clinic Judetean de Urgenta Cluj Napoca Reumatologie

    Cluj-Napoca, Cluj, 400006

  • Spitalul Clinic Judetean de Urgenta - "Sf.Apostol Andrei" Galati

    Galati, 800578

  • Spitalul Clinic de Recuperare Iasi

    Iași, 700661

  • Covamed Serv SRL

    Sfantu Gheorghe, Covasna, 520052

Other trials in Romania

Philippines10 sites
  • Perpetual Succour Hospital

    Cebu City, 6000

  • Brokenshire Integrated Health Ministries, Inc.

    Davao City, Davao DEL SUR, 8000

  • Davao Doctors Hospital

    Davao City, 8000

  • Iloilo Doctors' Hospital, Inc

    Iloilo City, Iloilo, 5000

  • St. Paul's Hospital of Iloilo, Inc.

    Iloilo City, 5000

  • Mary Mediatrix Medical Center

    Lipa City, Batangas, 4217

  • University of the Philippines Manila-Philippine General Hospital

    Manila, National Capital Region, 1000

  • Jose R. Reyes Memorial Medical Center-Rayuma Klinik

    Manila, National Capital Region, 1003

  • St. Luke's Medical Center

    Quezon City, National Capital Region, 1102

  • Far Eastern University - NRMF Medical Center

    Quezon City, National Capital Region, 1118

Other trials in Philippines

Bulgaria9 sites
  • UMHAT "Dr. Georgi Stranski" EAD

    Pleven, 5800

  • MHAT "Kaspela" EOOD

    Plovdiv, 4002

  • MHAT EUROHOSPITAL Plovdiv

    Plovdiv, 4004

  • MHAT Akta Medika OOD

    Rousse, 5400

  • MHAT Ruse AD

    Rousse, 7002

  • MHAT Shumen AD

    Shumen, 9700

  • NMTH Tsar Boris Clinic of Internal Diseases

    Sofia, 1233

  • MHAT Lyulin EAD

    Sofia, 1336

  • MHAT "Targovishte" AD

    Targovisthe, 7700

Other trials in Bulgaria

Australia6 sites
  • Royal Prince Alfred Hospital

    Camperdown, New South Wales, 2050

  • Emeritus Research

    Malvern East, Victoria, 3145

  • Pacific Private Clinic

    Southport, Queensland, 4215

  • QML Pathology

    Southport, Queensland, 4215

  • RK Will Pty Ltd

    Victoria Park, Western Australia, 6100

  • The Queen Elizabeth Hospital

    Woodville South, South Australia, 5011

Other trials in Australia

South Korea6 sites
  • Kyungpook National University Hospital

    Daegu, 41944

  • Daegu Catholic University Medical Center

    Daegu, 42472

  • Chonnam National University Hospital

    Gwangju, 61469

  • Inha University Hospital

    Jung-Gu, Incheon, 22332

  • Hanyang University Seoul Hospital

    Seoul, 04763

  • Konkuk University Medical Center

    Seoul, 05030

Other trials in South Korea

Spain6 sites
  • Complexo Hospitalario Universitario A Coruna

    A Coruña, 15006

  • Hospital Clinic de Barcelona

    Barcelona, 08036

  • Hospital Universitario Fundacion Jimenez Diaz

    Madrid, 28040

  • Hospital Regional Universitario de Malaga

    Málaga, 29009

  • Complejo Hospitalario Universitario de Santiago de Compostela, Hospital Clinico Universitario

    Santiago de Compostela, A Coruna, 15706

  • Hospital Infanta Luisa

    Seville, 41010

Other trials in Spain

Taiwan6 sites
  • Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation

    Hualien City, 97002

  • Kaohsiung Medical University Chung-Ho Memorial Hospital - New

    Kaohsiung City, 807

  • Kaohsiung Veterans General Hospital

    Kaohsiung City, 81362

  • Chung Shan Medical University Hospital

    Taichung, Taiwan ROC, 402

  • Taipei Veterans General Hospital

    Taipei, 11217

  • Chang Gung Medical Foundation - Linkou Branch

    Taoyuan County, 33305

Other trials in Taiwan

Argentina5 sites
  • Organizacion Medica de Investigacion S.A - OMI

    Buenos Aires, 1015

  • Atencion Integral en Reumatologia (AIR)

    CABA, Buenos Aires, C1426AAL

  • CER San Juan, Centro Polivalente de Asistencia e Investigacion Clinica

    San Juan, 5400

  • Centro Medico Privado de Reumatologia

    San Miguel de Tucumán, Tucumán Province, 4000

  • Centro Radiologico Luis Mendez Collado SRL

    San Miguel de Tucumán, Tucumán Province, 4000

Other trials in Argentina

Czechia5 sites
  • Revmatologie s.r.o.

    Brno, 63800

  • Revmacentrum MUDr. Mostera, s.r.o.

    Brno-Židenice, Czech Republic, 615 00

  • Revmatologicka ambulance

    Česká Lípa, 470 01

  • Vesalion, s.r.o.

    Ostrava- Moravska Ostrava, 702 00

  • Revmatologie

    Prague, 140 00

Other trials in Czechia

Thailand5 sites
  • Phramongkutklao Hospital

    Bangkok, Rajthevi, 10400

  • Cardiology Unit,Department of Medicine, Faculty of Medicine, Ramathibodi Hospital,Mahidol University

    Bangkok, 10400

  • Div. of Allergy Immunology and Rheumatology, Dept. of Medicine,

    Bangkok, 10400

  • Siriraj Hospital Mahidol University

    Bangkok, 10700

  • Songklanagarind Hospital - Prince of Songkhla University

    Songkhla, 90110

Other trials in Thailand

United Kingdom5 sites
  • The Royal Wolverhamptons NHS Trust

    Cannock, WS11 5XY

  • The Dudley Group NHS Foundation Trust

    Dudley, WEST Midlands, DY1 2HQ

  • The Leeds Teaching Hospitals NHS Trust

    Leeds, LS7 4SA

  • Aintree University Hospital NHS Foundation Trust

    Liverpool, L9 7AL

  • Royal Free London NHS Foundation Trust

    London, NW3 2QG

Other trials in United Kingdom

Chile4 sites
  • Quantum Research Ltda

    Puerto Varas, Los Lagos Region, 5550170

  • Quantum Research

    Puerto Varas, Los Lagos Region, 5550170

  • Prosalud

    Santiago, Santiago Metropolitan, 7510047

  • Estudios Clinicos Quinta Region Ltda.

    Viña del Mar, Valparaiso, 2520997

Other trials in Chile

Israel4 sites
  • Bnai Zion Medical Center

    Haifa, 31048

  • Rambam Health Care Campus

    Haifa, 3109601

  • Hadassah Medical Center

    Jerusalem, 91120

  • The Chaim Sheba Medical Center

    Tel HaShomer, 5262000

Other trials in Israel

Peru4 sites
  • Unidad de Investigacion en Medicina Interna y Enfermedades criticas-Hogar Clinica San Juan de Dios

    Arequipa, 04020

  • ABK REUMAR S.R.L. de Medicentro Biociencias_ BIO CIENCIAS PERU S.R.L.

    Lima, 21

  • Instituto Peruano del Hueso y la Articulacion

    Lima, 27

  • Investigaciones Clinicas S.A.C.

    Lima, 33

Other trials in Peru

Turkey (Türkiye)4 sites
  • Ankara Universitesi Tip Fakultesi Ibn-i Sina Hastanesi

    Ankara, 06100

  • Ondokuz Mayis Universitesi Tip Fakultesi Saglik Uyg. ve Eg.

    Samsun, 55139

  • Ondokuz Mayis Universitesi Tip Fakultesi Saglik Uygulama ve Egitim Merkezi

    Samsun, 55139

  • Cumhuriyet Universitesi Tip Fakultesi Hastanesi

    Sivas, 58140

Other trials in Turkey (Türkiye)

Estonia3 sites
  • Foundation Parnu Hospital

    Pärnu, 80010

  • East-Tallinn Central Hospital Ltd

    Tallinn, 11312

  • North Estonia Medical Centre Foundation

    Tallinn, 13419

Other trials in Estonia

Lithuania3 sites
  • Alytaus District S. Kudirkos Hospital

    Alytus, LT-62114

  • VAKK "Clinic of Dr. Kilda"

    Kaunas, LT-50128

  • PI Republican Siauliai Hospital

    Šiauliai, LT-76231

Other trials in Lithuania

Bosnia and Herzegovina2 sites
  • University Hospital Clinical Center Banja Luka

    Banja Luka, Republika Srpska, 78000

  • University Clinical Center Tuzla

    Tuzla, 75000

Other trials in Bosnia and Herzegovina

Canada2 sites
  • Kw Musculoskeletal Research Inc

    Kitchener, Ontario, N2M 5N6

  • Centre de Recherche Musculo-Squelettique

    Trois-Rivières, Quebec, G8Z 1Y2

Other trials in Canada

Latvia2 sites
  • Health Center 4

    Riga, LV-1012

  • ORTO clinic Ltd

    Riga, LV1005

Other trials in Latvia

About this study

Official title: A Phase 3b/4 Randomized Double Blind Study Of 5 Mg Of Tofacitinib With And Without Methotrexate In Comparison To Adalimumab With Methotrexate In Subjects With Moderately To Severely Active Rheumatoid Arthritis

To assess the efficacy of tofacitinib monotherapy or tofacitinib with methotrexate as compared to adalimumab with methotrexate. To compare the efficacy of tofacitinib monotherapy compared to tofacitinib combined with methotrexate. To compare effects on all health outcomes measures in the study. To evaluate the safety and tolerability of tofacitinib and adalimumab. To evaluate the safety of the zoster vaccine given prior to the initiation of tofacitinb or adalimumab.

Being tested
Tofacitinib with methotrexate, Tofacitinib without methotrexate, Adalimumab with methotrexate

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Tofacitinib with methotrexateDrug

    Tofacitinib 5 mg twice daily, oral for 12 months Methotrexate (previous stable dose 15-25 mg) every week, oral for 12 months Placebo for adalimumab every other week, subcutaneous for 12 months

  • Tofacitinib without methotrexateDrug

    Tofacitinib 5 mg twice daily, oral for 12 months Placebo for methotrexate (previous stable dose) every week, oral for 12 months Placebo for adalimumab every other week, subcutaneous for 12 months

  • Adalimumab with methotrexateBiological

    Placebo for tofacitinib twice daily, oral for 12 months Methotrexate (previous stable dose 15-25 mg) every week, oral for 12 months Adalimumab 40 mg every other week, subcutaneous for 12 months

Study groups in NCT02187055
Study groupRoleWhat they receive
Tofacitinib 5 mg twice daily with methotrexateExperimentalNot described
Receives: Drug: Tofacitinib with methotrexate
Tofacitinib 5 mg twice daily monotherapyExperimentalNot described
Receives: Drug: Tofacitinib without methotrexate
Adalimumab with methotrexateActive comparatorNot described
Receives: Biological: Adalimumab with methotrexate

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Percentage of Participants Achieving American College of Rheumatology Criteria 50% Improvement (ACR50) Response at Month 6

    ACR50 is a greater than or equal to (≥) 50 percent (%) improvement in tender joint count (TJC) or swollen joint count (SJC) and 50% improvement in 3 of the following 5 criteria: 1) physician's global assessment (PGA) of disease activity, 2) participant's assessment (PtGA) of disease activity, 3) participant's assessment of pain, 4) participant's assessment of functional disability via a health assessment questionnaire, and 5) C-reactive protein (CRP) at each visit.

    Measured: Month 6

Secondary outcomes (30)
  1. Change From Baseline in Simplified Disease Activity Index (SDAI) Value at Month 6

    SDAI is the numerical sum of five outcome parameters: TJC and SJC both based on a 28-joint assessment, PtGA and PGA both assessed on a 0 to 10 centimeter (cm) visual analogue scale (VAS) (higher scores indicate greater affection due to disease activity), and CRP (mg/dL). SDAI total score ranges from 0 to 86. SDAI less than or equal to (≤) 3.3 indicates disease remission, >3.4 to 11 indicates low disease activity, >11 to 26 indicates moderate disease activity, and >26 indicates high disease activity.

    Measured: Month 6

  2. Change From Baseline in Clinical Disease Activity Index (CDAI) Value at Month 6

    CDAI is the numerical sum of four outcome parameters: TJC and SJC both based on a 28-joint assessment, PtGA and PGA both assessed on a 0 to 10 cm VAS (higher scores indicate greater affection due to disease activity). CDAI total score ranges from 0 to 76. CDAI ≤2.8 indicates disease remission, >2.8 to 10 indicates low disease activity, >10 to 22 indicates moderate disease activity, and >22 indicates high disease activity.

    Measured: Month 6

  3. Change From Baseline in Disease Activity Score 28-4 (DAS28-4) Including CRP at Month 6

    DAS28-4 (CRP) was calculated from the SJC and TJC (both based on a 28-joint assessment), PtGA (assessed on a 0 to 10 cm VAS; higher scores indicate greater affection due to disease activity) and CRP (mg/L) using the following: DAS28-4(CRP) = 0.56*sqrt(TJC28) + 0.28*sqrt(SJC28) + 0.36*ln(CRP+1) + 0.014* PtGA (millimeters [mm]) + 0.96. Total score range: 0 to 9.4, higher score indicated higher disease activity. DAS28-4 (CRP) ≤3.2 indicates low disease activity, >3.2 to 5.1 indicates moderate to high disease activity, and less than (<) 2.6 indicates remission.

    Measured: Month 6

  4. Change From Baseline in Disease Activity Score 28-4 (DAS28-4) Including Erythrocyte Sedimentation Rate (ESR) at Month 6

    DAS28-4 (ESR) was calculated from the SJC and TJC (both based on a 28-joint assessment), PtGA (assessed on a 0 to 10 cm VAS; higher scores indicate greater affection due to disease activity) and ESR (mm/hour) using the following: DAS28-4(ESR) = 0.56*sqrt(TJC28) + 0.28*sqrt(SJC28) + 0.70*ln(ESR) + 0.014* PtGA (mm). Total score range: 0 to 9.4, higher score indicated higher disease activity. DAS28-3 (ESR) ≤3.2 indicates low disease activity, >3.2 to 5.1 indicates moderate to high disease activity, and <2.6 indicates remission.

    Measured: Month 6

  5. Percentage of Participants Achieving Observed American College of Rheumatology-European League Against Rheumatism (ACR-EULAR) Boolean Remission Criteria at Month 6

    To meet the ACR-EULAR Boolean remission criteria, a participant must satisfy all of the following: TJC ≤1 and SJC ≤1 (both based on a 28-joint assessment), CRP ≤1 mg/dL, and PtGA ≤1 on a 0 to 10 cm VAS (higher scores indicate greater affection due to disease activity).

    Measured: Month 6

  6. Percentage of Participants Achieving SDAI ≤3.3 at Month 6

    SDAI is the numerical sum of five outcome parameters: TJC and SJC both based on a 28-joint assessment, PtGA and PGA both assessed on a 0 to 10 cm VAS (higher scores indicate greater affection due to disease activity), and CRP (mg/dL). SDAI total score ranges from 0 to 86. SDAI ≤3.3 indicates disease remission.

    Measured: Month 6

  7. Percentage of Participants Achieving CDAI ≤2.8 at Month 6

    CDAI is the numerical sum of four outcome parameters: TJC and SJC both based on a 28-joint assessment, PtGA and PGA both assessed on a 0 to 10 cm VAS (higher scores indicate greater affection due to disease activity). CDAI total score ranges from 0 to 76. CDAI ≤2.8 indicates disease remission.

    Measured: Month 6

  8. Percentage of Participants Achieving DAS28-4 (ESR) <2.6 at Month 6

    DAS28-4 (ESR) was calculated from the SJC and TJC (both based on a 28-joint assessment), PtGA (assessed on a 0 to 10 cm VAS; higher scores indicate greater affection due to disease activity) and ESR (mm/hour) using the following: DAS28-4(ESR) = 0.56*sqrt(TJC28) + 0.28*sqrt(SJC28) + 0.70*ln(ESR) + 0.014* PtGA (mm). Total score range: 0 to 9.4, higher score indicates higher disease activity. DAS28-4 (ESR) <2.6 indicates disease remission.

    Measured: Month 6

  9. Percentage of Participants Achieving DAS28-4 (CRP) <2.6 at Month 6

    DAS28-4 (CRP) was calculated from the SJC and TJC (both based on a 28-joint assessment), PtGA (assessed on a 0 to 10 cm VAS; higher scores indicate greater affection due to disease activity) and CRP (mg/L) using the following: DAS28-4(CRP) = 0.56*sqrt(TJC28) + 0.28*sqrt(SJC28) + 0.36*ln(CRP+1) + 0.014* PtGA (mm) + 0.96. Total score range: 0 to 9.4, higher score indicates higher disease activity. DAS28-4 (CRP) <2.6 indicates remission.

    Measured: Month 6

  10. Percentage of Participants Achieving SDAI ≤11 at Month 6

    SDAI is the numerical sum of five outcome parameters: TJC and SJC both based on a 28-joint assessment, PtGA and PGA both assessed on a 0 to 10 cm VAS (higher scores indicate greater affection due to disease activity), and CRP (mg/dL). SDAI total score ranges from 0 to 86. SDAI ≤3.3 indicates disease remission, >3.4 to 11 indicates low disease activity.

    Measured: Month 6

  11. Percentage of Participants Achieving CDAI ≤10 at Month 6

    CDAI is the numerical sum of four outcome parameters: TJC and SJC both based on a 28-joint assessment, PtGA and PGA both assessed on a 0 to 10 cm VAS (higher scores indicate greater affection due to disease activity). CDAI total score ranges from 0 to 76. CDAI ≤2.8 indicates disease remission, >2.8 to 10 indicates low disease activity.

    Measured: Month 6

  12. Percentage of Participants Achieving DAS28-4 (ESR) ≤3.2 at Month 6

    DAS28-4 (ESR) was calculated from the SJC and TJC (both based on a 28-joint assessment), PtGA (assessed on a 0 to 10 cm VAS; higher scores indicate greater affection due to disease activity) and ESR (mm/hour) using the following: DAS28-4(ESR) = 0.56*sqrt(TJC28) + 0.28*sqrt(SJC28) + 0.70*ln(ESR) + 0.014* PtGA (mm). Total score range: 0 to 9.4, higher score indicates higher disease activity. DAS28-4 (ESR) ≤3.2 indicates low disease activity.

    Measured: Month 6

  13. Percentage of Participants Achieving DAS28-4 (CRP) ≤3.2 at Month 6

    DAS28-4 (CRP) was calculated from the SJC and TJC (both based on a 28-joint assessment), PtGA (assessed on a 0 to 10 cm VAS; higher scores indicate greater affection due to disease activity) and CRP (mg/L) using the following: DAS28-4(CRP) = 0.56*sqrt(TJC28) + 0.28*sqrt(SJC28) + 0.36*ln(CRP+1) + 0.014* PtGA + 0.96. Total score range: 0 to 9.4, higher score indicated higher disease activity. DAS28-4 (CRP) ≤3.2 indicates low disease activity.

    Measured: Month 6

  14. Percentage of Participants Achieving American College of Rheumatology Criteria 20% Improvement (ACR20) Response at Month 6

    ACR20 response is a ≥20% improvement in TJC or SJC and 20% improvement in 3 of the following 5 criteria: 1) PGA of disease activity, 2) PtGA of disease activity, 3) participant's assessment of pain, 4) participant's assessment of functional disability via a health assessment questionnaire, and 5) CRP at each visit.

    Measured: Month 6

  15. Percentage of Participants Achieving American College of Rheumatology Criteria 70% Improvement (ACR70) Response at Month 6

    ACR70 response is a ≥70% improvement in TJC or SJC and 70% improvement in 3 of the following 5 criteria: 1) PGA of disease activity, 2) PtGA of disease activity, 3) participant's assessment of pain, 4) participant's assessment of functional disability via a health assessment questionnaire, and 5) CRP at each visit.

    Measured: Month 6

  16. Change From Baseline in Health Assessment Questionnaire - Disability Index (HAQ-DI) at Month 6

    The HAQ-DI is a participant-reported assessment of ability to perform tasks in 8 categories of daily living activities: dressing and grooming, arising, eating, walking, reach, grip, hygiene and other activities over the past week. Each activity category consists of 2 to 3 items. Each item is scored on 4-point scale from 0 to 3: 0=no difficulty; 1=some difficulty; 2=much difficulty; 3=unable to do. Any activity requiring assistance from another individual or the use of an assistive device adjusts to a minimum score of 2 to represent a more limited functional status. Overall score was computed as the sum of domain scores and divided by the number of domains answered. Total possible score ranges from 0 to 3 where 0 = least difficulty and 3 = extreme difficulty.

    Measured: Month 6

  17. Percentage of Participants Achieving an HAQ-DI Decrease of at Least 0.22 at Month 6

    The HAQ-DI is a participant-reported assessment of ability to perform tasks in 8 categories of daily living activities: dressing and grooming, arising, eating, walking, reach, grip, hygiene and other activities over the past week. Each activity category consists of 2 to 3 items. Each item is scored on 4-point scale from 0 to 3: 0=no difficulty; 1=some difficulty; 2=much difficulty; 3=unable to do. Any activity requiring assistance from another individual or the use of an assistive device adjusts to a minimum score of 2 to represent a more limited functional status. Overall score was computed as the sum of domain scores and divided by the number of domains answered. Total possible score ranges from 0 to 3 where 0 = least difficulty and 3 = extreme difficulty. A decrease of 0.22 or more is considered a positive response.

    Measured: Month 6

  18. Change From Baseline in the Short-Form-36 (SF-36) Health Survey, Physical Component Score at Month 6

    The SF-36 health survey is a 36-item measure that evaluates 8 domains: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role emotional, and mental health. The health domains are aggregated into two summary scores known as the physical component summary (PCS) score and the mental component summary (MCS) score. Normalized domain scores, PCS and MCS scores are used in the analyses. The component and domain scores were scored using the United States (US) 1998 general population norms. The resulting norm-based scores for both the SF-36 version 2 (v2) and SF-36 health domain scales and component summary measures have means of 50 and standard deviations of 10. A higher PCS score represents better physical health status.

    Measured: Month 6

  19. Change From Baseline in the SF-36 Health Survey, Mental Component Score at Month 6

    The SF-36 health survey is a 36-item measure that evaluates 8 domains: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role emotional, and mental health. The health domains are aggregated into two summary scores known as the PCS score and the MCS score. Normalized domain scores, PCS and MCS scores are used in the analyses. The component and domain scores were scored using the US 1998 general population norms. The resulting norm-based scores for both the SF-36 v2 and SF-36 health domain scales and component summary measures have means of 50 and standard deviations of 10. A higher MCS score represents better physical health status.

    Measured: Month 6

  20. Change From Baseline in the SF-36 Health Survey, Physical Functioning Domain Score at Month 6

    SF-36v2 acute is a 36-item measure evaluating 8 domains: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role emotional, and mental health. The 10 items of the physical functioning scale represent levels and kinds of limitations between extremes of physical activities, including lifting and carrying groceries; climbing stairs; bending, kneeling, or stooping; walking moderate distances; self-care limitations. The physical functioning items capture the presence and extent of physical limitations using a 3-level response continuum. The domain scores were scored using the US 1998 general population norms. The resulting norm-based scores for both the SF-36 v2 and SF-36 health domain scales and component summary measures have means of 50 and standard deviations of 10. A higher physical functioning domain score represents better physical functioning.

    Measured: Month 6

  21. Change From Baseline in the SF-36 Health Survey, Role Physical Domain Score at Month 6

    SF-36v2 acute is a 36-item measure evaluating 8 domains: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role emotional, and mental health. The 4-item role physical scale covers an array of physical health-related role limitations, including: a) limitations in the kind of work or other usual activities; b) reductions in the amount of time spent on work or other usual activities; c) difficulty performing work or other usual activities; and d) accomplishing less. Items in the role physical scale are answered on a 5-point scale. The domain scores were scored using the US 1998 general population norms. The resulting norm-based scores for both the SF-36 v2 and SF-36 health domain scales and component summary measures have means of 50 and standard deviations of 10. A higher role physical domain score represents better role physical functioning.

    Measured: Month 6

  22. Change From Baseline in the SF-36 Health Survey, Bodily Pain Domain Score at Month 6

    The SF-36v2 acute is a 36-item measure that evaluates 8 domains: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role emotional, and mental health. The bodily pain scale comprises of 2 items pertaining to the intensity of bodily pain and extent of interference with normal work activities. The domain scores were scored using the US 1998 general population norms. The resulting norm-based scores for both the SF-36 v2 and SF-36 health domain scales and component summary measures have means of 50 and standard deviations of 10. A higher bodily pain domain score represents less bodily pain.

    Measured: Month 6

  23. Change From Baseline in the SF-36 Health Survey, General Health Domain Score at Month 6

    The SF-36v2 acute is a 36-item measure that evaluates 8 domains: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role emotional, and mental health. The general health scale consists of 5 items including a rating of health and 4 items addressing the respondent's view and expectations of his or her health. The domain scores were scored using the US 1998 general population norms. The resulting norm-based scores for both the SF-36 v2 and SF-36 health domain scales and component summary measures have means of 50 and standard deviations of 10. A higher general health domain score represents better general health perceptions.

    Measured: Month 6

  24. Change From Baseline in the SF-36 Health Survey, Vitality Domain Score at Month 6

    The SF-36v2 acute is a 36-item measure that evaluates 8 domains: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role emotional, and mental health. The 4-item measure of vitality captures a broad range of subjective evaluations of well-being from feelings of tiredness and being worn out to feeling full of energy all or most of the time. The domain scores were scored using the US 1998 general population norms. The resulting norm-based scores for both the SF-36 v2 and SF-36 health domain scales and component summary measures have means of 50 and standard deviations of 10. A higher vitality domain score represents better vitality.

    Measured: Month 6

  25. Change From Baseline in the SF-36 Health Survey, Social Functioning Domain Score at Month 6

    The SF-36v2 acute is a 36-item measure that evaluates 8 domains: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role emotional, and mental health. The 2-item social functioning scale assesses health-related effects on quantity and quality of social activities. The domain scores were scored using the US 1998 general population norms. The resulting norm-based scores for both the SF-36 v2 and SF-36 health domain scales and component summary measures have means of 50 and standard deviations of 10. A higher social functioning domain score represents better social functioning.

    Measured: Month 6

  26. Change From Baseline in the SF-36 Health Survey, Role Emotional Domain Score at Month 6

    The SF-36v2 acute is a 36-item measure that evaluates 8 domains: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role emotional, and mental health. The 3-item role emotional scale assesses mental health-related role limitations in terms of a) time spent in work or other usual activities; b) amount of work or activities accomplished; c) care with which work or other activities were performed. All 3 items are answered on a 5-point scale. The domain scores were scored using the US 1998 general population norms. The resulting norm-based scores for both the SF-36 v2 and SF-36 health domain scales and component summary measures have means of 50 and standard deviations of 10. A higher role emotional domain score represents better role emotional functioning.

    Measured: Month 6

  27. Change From Baseline in the SF-36 Health Survey, Mental Health Domain Score at Month 6

    The SF-36v2 acute is a 36-item measure that evaluates 8 domains: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role emotional, and mental health. The 5-item mental health scale includes 1 or more items from each of 4 major mental health dimensions: anxiety, depression, loss of behavioral/emotional control, and psychological well-being. All items are answered on a 5-point scale. The domain scores were scored using the US 1998 general population norms. The resulting norm-based scores for both the SF-36 v2 and SF-36 health domain scales and component summary measures have means of 50 and standard deviations of 10. A higher mental health domain score represents better mental health functioning.

    Measured: Month 6

  28. Change From Baseline in the Work Productivity and Activity Impairment (WPAI) Questionnaire at Month 6

    The WPAI: Rheumatoid Arthritis is a 6 item questionnaire that is specific for rheumatoid arthritis and yields four types of scores: absenteeism, presenteesism (impairment at work/reduced job effectiveness), work productivity loss and activity impairment. WPAI outcomes are expressed as impairment percentages ranging from 0 to 100, with higher numbers indicating greater impairment and less productivity.

    Measured: Month 6

  29. Change From Baseline in the EuroQol European Quality of Life-5 Dimensions (EuroQol EQ-5D) at Month 6

    The EQ-5D is a participant rated questionnaire to assess health-related quality of life in terms of a single utility score. Health State Profile component assesses level of current health for 5 domains: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression; 1 indicates better health state (no problems); 3 indicates worst health state ("confined to bed"). This profile of scores across the 5-dimensions (e.g. 11231, 33212, etc.) is transformed into a single health utility score using a formula developed by the EuroQol Group that applies country specific preference weights. Score is transformed and results in a total score range -0.594 to 1.000; higher score indicates a better health state. The VAS component rated the current health state on a scale ranging from 0 (worst imaginable health state) to 100 (best imaginable health state); higher scores indicating a better health state.

    Measured: Month 6

  30. Change From Baseline in the Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) Scale Total Score at Month 6

    FACIT-F is a 13-item questionnaire. Participants scored each item on a 5-point scale: 0 (not at all) to 4 (very much). The larger the participant's response (with the exception of 2 negatively stated), the greater the participant's fatigue. For all questions, except for the 2 negatively stated ones, the code was reversed and a new score was calculated as (4 minus the participant's response). The sum of all responses resulted in the FACIT-Fatigue score for a total possible score of 0 (worse score) to 52 (better score).

    Measured: Month 6

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted10 Jul 2014 (estimated)
  2. Study startAug 2014
  3. Primary completionDec 2016
  4. Study completionDec 2016

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
Quadruple blind
Who is masked
Participant, Care provider, Investigator, Outcomes assessor
Enrolment
1,152 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT02187055
Sponsor's protocol ID
A3921187
Other IDs
2014-000358-13, ORAL STRATEGY, 2014
Acronym
ORAL STRATEGY
Status last verified
May 2018
First submitted
8 Jul 2014
Last updated
27 Jun 2018
Data monitoring committee
Yes

Publications

  • Wright G, Mysler E, Roberts KD, Shelbaya A, Sweet L, Masri KR. Impact of the Sociodemographic Index on Efficacy/Safety of Tofacitinib in Patients with Rheumatoid Arthritis: Post Hoc Analysis of Phase 2/3/3b/4 Studies. Rheumatol Ther. 2026 Oct 16. doi: 10.1007/s40744-026-00881-y. Online ahead of print.

    PubMed 42888330
  • Takeuchi T, Tanaka Y, Yamanaka H, Yamaoka K, Sugiyama N, Iikuni N, Toyoizumi S, Kwok K, Tsai WC, Mysler E, Moots RJ, Smolen JS, Fleischmann R. Efficacy and Safety of Tofacitinib and Adalimumab in Rheumatoid Arthritis by Body Mass Index-Normalized Methotrexate Dose: A Post Hoc Analysis. Rheumatol Ther. 2026 Apr;13(2):423-434. doi: 10.1007/s40744-025-00823-0. Epub 2026 Jan 22.

    PubMed 41565911
  • Hetland ML, Strangfeld A, Bonfanti G, Soudis D, Deuring JJ, Edwards RA. Machine learning prediction and explanatory models of serious infections in patients with rheumatoid arthritis treated with tofacitinib. Arthritis Res Ther. 2024 Aug 27;26(1):153. doi: 10.1186/s13075-024-03376-9.

    PubMed 39192350
  • Wright GC, Mysler E, Kwok K, Cadatal MJ, Germino R, Yndestad A, Kinch CD, Ogdie A. Impact of Race on the Efficacy and Safety of Tofacitinib in Rheumatoid Arthritis: Post Hoc Analysis of Pooled Clinical Trials. Rheumatol Ther. 2024 Oct;11(5):1135-1164. doi: 10.1007/s40744-024-00677-y. Epub 2024 Jul 3.

    PubMed 38958913
  • Pope J, Finckh A, Silva-Fernandez L, Mandl P, Fan H, Rivas JL, Valderrama M, Montoro M. Tofacitinib Monotherapy in Rheumatoid Arthritis: Clinical Trials and Real-World Data Contextualization of Patients, Efficacy, and Treatment Retention. Open Access Rheumatol. 2024 Jun 11;16:115-126. doi: 10.2147/OARRR.S446431. eCollection 2024.

    PubMed 38883150
  • Citera G, Jain R, Irazoque F, Madariaga H, Gruben D, Wang L, Stockert L, Santana K, Ebrahim A, Ponce de Leon D. Tofacitinib Efficacy in Patients with Rheumatoid Arthritis and Probable Depression/Anxiety: Post Hoc Analysis of Phase 3 and 3b/4 Randomized Controlled Trials. Rheumatol Ther. 2024 Feb;11(1):35-50. doi: 10.1007/s40744-023-00612-7. Epub 2023 Nov 5.

    PubMed 37925660
  • Kristensen LE, Danese S, Yndestad A, Wang C, Nagy E, Modesto I, Rivas J, Benda B. Identification of two tofacitinib subpopulations with different relative risk versus TNF inhibitors: an analysis of the open label, randomised controlled study ORAL Surveillance. Ann Rheum Dis. 2023 Jul;82(7):901-910. doi: 10.1136/ard-2022-223715. Epub 2023 Mar 17.

    PubMed 36931693
  • Dougados M, Taylor PC, Bingham CO 3rd, Fallon L, Brault Y, Roychoudhury S, Wang L, Kessouri M. The effect of tofacitinib on residual pain in patients with rheumatoid arthritis and psoriatic arthritis. RMD Open. 2022 Sep;8(2):e002478. doi: 10.1136/rmdopen-2022-002478.

    PubMed 36814062
  • Hansen KE, Mortezavi M, Nagy E, Wang C, Connell CA, Radi Z, Litman HJ, Adami G, Rossini M. Fracture in clinical studies of tofacitinib in rheumatoid arthritis. Ther Adv Musculoskelet Dis. 2022 Dec 27;14:1759720X221142346. doi: 10.1177/1759720X221142346. eCollection 2022.

    PubMed 36601090
  • Curtis JR, Yamaoka K, Chen YH, Bhatt DL, Gunay LM, Sugiyama N, Connell CA, Wang C, Wu J, Menon S, Vranic I, Gomez-Reino JJ. Malignancy risk with tofacitinib versus TNF inhibitors in rheumatoid arthritis: results from the open-label, randomised controlled ORAL Surveillance trial. Ann Rheum Dis. 2023 Mar;82(3):331-343. doi: 10.1136/ard-2022-222543. Epub 2022 Dec 5.

    PubMed 36600185
  • Winthrop KL, Yndestad A, Henrohn D, Danese S, Marsal S, Galindo M, Woolcott JC, Jo H, Kwok K, Shapiro AB, Jones TV, Diehl A, Su C, Panes J, Cohen SB. Influenza Adverse Events in Patients with Rheumatoid Arthritis, Ulcerative Colitis, or Psoriatic Arthritis in the Tofacitinib Clinical Development Programs. Rheumatol Ther. 2023 Apr;10(2):357-373. doi: 10.1007/s40744-022-00507-z. Epub 2022 Dec 17.

    PubMed 36526796
  • Bessette L, Mysler E, Kinch CD, Kwok K, Lukic T, On PV, van Vollenhoven RF. Impact of Tofacitinib on Components of the ACR Response Criteria: Post Hoc Analysis of Phase III and Phase IIIb/IV Trials. J Rheumatol. 2022 Jun;49(6):566-576. doi: 10.3899/jrheum.210707. Epub 2022 Mar 1.

    PubMed 35232809
  • Dikranian A, Gold D, Bessette L, Nash P, Azevedo VF, Wang L, Woolcott J, Shapiro AB, Szumski A, Fleishaker D, Wollenhaupt J. Frequency and Duration of Early Non-serious Adverse Events in Patients with Rheumatoid Arthritis and Psoriatic Arthritis Treated with Tofacitinib. Rheumatol Ther. 2022 Apr;9(2):411-433. doi: 10.1007/s40744-021-00405-w. Epub 2021 Dec 17.

    PubMed 34921355
  • Winthrop KL, Curtis JR, Yamaoka K, Lee EB, Hirose T, Rivas JL, Kwok K, Burmester GR. Clinical Management of Herpes Zoster in Patients With Rheumatoid Arthritis or Psoriatic Arthritis Receiving Tofacitinib Treatment. Rheumatol Ther. 2022 Feb;9(1):243-263. doi: 10.1007/s40744-021-00390-0. Epub 2021 Dec 6.

    PubMed 34870800
  • Takeuchi T, Fleischmann R, Iikuni N, Shi H, Soma K, Paulissen J, Hirose T, Smolen JS. Differences and similarities in clinical and functional responses among patients receiving tofacitinib monotherapy, tofacitinib plus methotrexate, and adalimumab plus methotrexate: a post hoc analysis of data from ORAL Strategy. Arthritis Res Ther. 2021 Aug 24;23(1):220. doi: 10.1186/s13075-021-02591-y.

    PubMed 34429160

Questions about this trial

What is this clinical trial studying?

A Phase 4 study testing Tofacitinib with methotrexate, Tofacitinib without methotrexate and Adalimumab with methotrexate in people with Rhematoid Arthritis, run by Pfizer at 215 sites in 25 countries.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 27 Jun 2018. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 215 sites in United States, Poland, Russia, Mexico, South Africa and 20 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 4 studies take place after a treatment is approved, to learn more about its long-term benefits and risks in everyday use.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

Yes. Results are posted in the registry (first posted 27 Jun 2018). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Percentage of Participants Achieving American College of Rheumatology Criteria 50% Improvement (ACR50) Response at Month 6 (time frame: Month 6). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT02187055, which also lists 20 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 27 Jun 2018.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in